Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
IP Group unveils maiden dividend after bumper results

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
IP Group (IPO) 122.6p
Gain to date: 47.7%
Original entry point: Buy at 83p, 15 October 2020
Developer of intellectual property-based ventures IP Group (IPO) is trading at its highest level since 2018, rewarding our positive call on the stock in October 2020.
The latest run for the shares followed a strong set of full-year results (10 Mar). The company even unveiled a maiden dividend after swinging to an annual profit as portfolio gains boosted net asset value.
Jefferies notes IP Group’s 15% stake in its main holding, biotech Oxford Nanopore, is being valued ‘well short’ of the investment bank’s estimated $5.4 billion valuation for the company.
IP Group’s net assets increased 16% to £1.3 billion or 125.3p per share during 2020 and it saw record cash realisations of £191 million from its investments.
The company is to seek approval to undertake share buybacks should the shares trade below net asset value per share.
Numis analyst Stefan Hamill commented: ‘Two new unicorns emerged in the portfolio, Ceres Power (CWR:AIM) and Hinge Health, validating IP Group’s ability to identify and build winners beyond Oxford Nanopore.’
SHARES SAYS: Still a buy.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.